



INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

(Use several sheets if necessary)

PTO Form 1449

Attorney Docket No.
038134-5005

Serial No.
10/021 312

Applicants

Applicants

Filing Date

Filing Date
December 19, 2001

Page 2 of 2

U.S. PATENT DOCUMENTS							
Examiner Initials	Document Number	Date mm/dd/yy	Name	Class	Sub Class	Filing Date mm/dd/yy	
B	5,691,316	11/25/97	Agrawal et al.	514	44	11/17/94	
B	5,608,015	03/04/97	Yoshinaga	526	75	05/04/94	
B	5,276,088	01/04/94	Yoshinaga	525	54.3	05/20/91	

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
	Document Number	Date mm/dd/yy	Country	Class	Sub Class	Translation YES	NO
<i>B</i>	WO 00/01734	01/13/00	PCT	RECEIVED			
<i>MPD</i>	WO 96/09073	03/28/96	PCT				
	1 390 479	04/16/75	UK	AUG 22 2000			
				TECH CENTER 1000/2000			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
Husain et al., "Complete," 1978.

Husain, et al., "Complexation of Doxorubicin with β - and γ -Cyclodextrins," *Applied Spectroscopy*, Vol. 46, No. 4, pp. 652-658, (1992)

Hwang, et al., "Effects of Structure of β -Cyclodextrin-Containing Polymers on Gene Delivery," Bioconjugate Chem., Vol. 12, No. 2, pp. 280-290 (2001)

Ooya, et al., "Synthesis and Characterization of an Oligopeptide-terminated Polyrotaxane as a Drug Carrier," *Polym. Adv. Technol.*, Vol. 11, pp. 642-651 (2000)

Pun, et al., "Development of a Nonviral Gene Delivery Vehicle for Systemic Application," *Bioconjugate Chem.*, Vol. 13, pp. 630-639. (2002)

Sandier, "Interaction between an Adamantane End-Capped Poly(ethylene oxide) and a β -Cyclodextrin Polymer," *Langmuir*, Vol 16, No. 4, pp. 1634-1642 (2000)
Tabushi et al. "Artificial Receptor Recognition by Cyclodextrins," *J Am Chem Soc*, Vol. 124, pp. 656-659, (2002)

Tanabe et al., "Artificial Receptor Recognizing Hydrophobic Carbonyl Compounds," *Journal of Organic Chemistry*, 51 (10), pp. 1918-1921 (1986).

Tojima, et al., "Preparation of an α -Cyclodextrin-Linked Chitosan Derivative via Reductive Amination Strategy," *J. Polym. Sci. Part A: Polym. Chem.*, Vol. 36, pp. 1965-1968 (1998).

Torchilin, et al., "TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors," PNAS, Vol. 98, No. 15, pp. 8786-8791 (2001)

Uekama, et al., "Cyclodextrin Drug Carrier Systems," Chem. Rev., 98, pp. 2045-2076 (1998);
Zanta, et al., "*In Vitro* Gene Delivery to Hematopoietic Cells," *Gene Ther.*, 10, 103-110 (2003).

Zarita, et al., "In Vitro Gene Delivery to Hepatocytes with Galactosylated Polyethylenimine," *Bioconjugate Chem.*, Vol. 8, pp. 839-844 (1997)

Zhang, et al., "Enthalpic Domination of the Chelate Effect in Cyclodextrin Dimers," *J. Am. Chem. Soc.*, Vol. 115, pp. 9353-9354 (1993)

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

PTO Form 1449

Attorney Docket No.
038134-5005Serial No.
10/021,312Applicants
Suzie HWANG PUN et al.

Page 1 of 2

AUG 21 2002

Filing Date
December 19, 2001Group
1632

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date mm/dd/yy	Name	Class	Sub Class	Filing Date mm/dd/yy
K	2001/0034333	10/25/01	Kosak	514	44	02/01/01
	2001/0044412	11/22/01	Wolff et al.	514	44	11/29/00
	6,132,734	10/17/00	Thomas et al.	424	275.1	06/02/95
	6,060,597	05/09/00	Tobe et al.	536	46	06/30/98
	6,048,736	04/11/00	Kosak	436	536	12/30/98
	5,880,154	03/09/99	Boukrinskaia et al.	514	561	02/01/94
B	5,855,900	01/05/99	Nobuhiko	424	425	5/12/95
	5,698,535	12/16/97	Geczy et al.	514	58	04/25/95

FOREIGN PATENT DOCUMENTS

Document Number	Date mm/dd/yy	Country	Class	Sub Class	Translation YES NO
WO 01/37665	05/31/01	PCT			
WO 00/75164	12/14/00	PCT			
WO 00/75162	12/14/00	PCT	AUG 22 2002		
WO 00/40962	07/13/00	PCT	TECH CENTER 1600/2900		✓ (abstract only)
WO 00/33885	06/15/00	PCT			


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Amiel, et al., "Associations Between Hydrophobic End-Capped Polyethylene Oxide and Water Soluble β Cyclodextrin Polymers," <u>Int. J. Polymer Analysis & Characterization</u> , Vol. 1, pp. 289-300 (1995)
	Amiel, et al., "New Associating Polymer Systems Involving Water Soluble β -Cyclodextrin Polymers," <u>Journal of Inclusion Phenomena and Molecular Recognition in Chemistry</u> , Vol. 25, pp. 61-67(1996)
	Amiel, et al., "Association between amphiphilic poly(ethylene oxide) and β -cyclodextrin polymers: aggregation and phase separation," <u>Advances in Colloid and Interface Science</u> , 79, pp. 105-122 (1999)
	Boussif, et al., "A versatile vector for gene and oligonucleotide transfer into cells in culture and <i>in vivo</i> : Polyethylenimine," <u>Proceedings of the National Academy of Sciences</u> , Vol. 92, No. 16, pp. 7297-7301 (1995)
	Breslow, et al., "Cholesterol Recognition and Binding by Cyclodextrin Dimers," <u>J. Am. Chem. Soc.</u> , Vol. 118, pp. 8495-8496 (1996)
	Cserháti, "Charge-Transfer Chromatographic Study of the Complex Formation of Some Anticancer Drugs with γ -Cyclodextrin," <u>Analytical Biochemistry</u> , 225, pp. 328-332 (1995)
	Finsinger, et al., "Protective copolymers for nonviral gene vectors: synthesis, vector characterization and application in gene delivery," <u>Gene Therapy</u> , Vol. 7, pp. 1183-1192 (2000)
	Fisher, "A versatile system for receptor-mediated gene delivery permits increased entry of DNA into target cells, enhanced delivery to the nucleus and elevated rates of transgene expression," <u>Gene Therapy</u> , Vol. 7, pp. 1337-1343 (2000)
	Gonzalez, et al., "New Class of Polymers for the Delivery of Macromolecular Therapeutics," <u>Bioconjugate Chem.</u> , Vol. 10, No. 6, pp. 1068-1074 (1999)

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/021312
Filing Date	December 19, 2001
First Named Inventor	Suzie Hwang Pun
Art Unit	1632
Examiner Name	Not Yet Assigned

Attorney Docket Number CTCH-P01-013

TECH CENTER 1600/2900

MAR 11 2003

RECEIVED

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹Applicant's unique citation designation number (optional). ²See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>DP</i>	AA	"Amantadine," in The Merck Index, 11th ed., Merck Research Laboratories, p. 60: No. 380 (1989).	
<i>DP</i>	AB	"Adamantane," in The Merck Index, 11th ed., Merck Research Laboratories, p. 24: No. 140 (1989).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>[Signature]</i>	Date Considered	11/5/04
--------------------	--------------------	-----------------	---------